文献速递前列腺癌

临床低危前列腺癌病理升级或分期升高对转移和癌症特异性死亡的影响

Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
PubMed 文献 · BJU Int · 2018-06-22

结果显示,临床低危患者即使出现不良病理特征,其转移和死亡风险仍显著低于中高危患者,分别降低约50%和约70%,且与无病理升级的低危患者无实质差异。

要点

  • 临床低危患者病理升级或分期升高后转移风险降低约50%,死亡风险降低约70%。
  • 仅升级至Gleason评分≥8、精囊侵犯或淋巴结侵犯与不良结局相关,但发生率低。
  • 病理升级/分期升高不应作为咨询主动监测利弊的主要终点。

核心结论

  • 临床低危患者出现病理升级或分期升高时,其肿瘤学结局显著优于治疗前中高危患者,且与无病理升级的低危患者无实质差异。

主要发现

  • 在具有不良病理特征的患者中,临床低危者的转移风险比中高危者降低约50%,死亡风险降低约70%。
  • 临床低危患者中,仅病理升级至Gleason评分≥8、精囊侵犯或淋巴结侵犯与不良结局相关,但这些再分类罕见。

关键数值与推荐

  • 不良病理特征定义为Gleason评分≥7、≥pT3或淋巴结侵犯。
  • 临床风险分层采用D'Amico标准(低危 vs 中/高危)。

临床怎么用

  • 临床低危患者出现病理升级或分期升高时,不应据此过度解读为高转移或死亡风险,应结合治疗前风险综合评估。
  • 该结果提示不宜将病理升级/分期升高作为咨询主动监测利弊的主要终点。

局限性

  • 回顾性研究设计。
  • 仅纳入行根治性前列腺切除术的患者,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if the presence of adverse pathological features in patients eligible for active surveillance (AS) are prognostic of poor oncological outcomes, independent of pretreatment risk. PATIENTS AND METHODS: A retrospective analysis was performed on patients who underwent radical prostatectomy (RP) at two institutions (Cleveland Clinic Foundation and Memorial Sloan Kettering Cancer Center) between 1987 and 2008, and who had subsequent follow-up. Rates of biochemical recurrence, metastasis and death from prostate cancer were compared amongst patients with adverse pathological features (Gleason score ≥7, ≥pT3, or lymph node invasion) based on D'Amico clinical risk (low vs intermediate/high). We also compared survival outcomes between patients with and without pathological upgrading/upstaging amongst D'Amico low-risk patients. Univariate and multivariable Cox regression models were used to assess the association between clinical risk, pathological reclassification, and oncological outcomes. RESULTS: We identified 16 341 patients who underwent RP, of whom 6 371 were clinically low-risk. Adverse outcomes in men with adverse pathological features were significantly lower in those with low clinical risk, with an ~50% and ~70% reduction in the risk of metastasis and death, respectively. Only pathological upgrading/upstaging to Gleason score ≥8, seminal vesicle invasion, and lymph node invasion from clinical low-risk disease, were associated with adverse outcomes. However, these types of reclassification were rare. CONCLUSION: Clinical low-risk patients with pathological upgrading/upstaging have substantially lower rates of important oncological outcomes compared to those with higher pretreatment risk and not substantially different than low-risk patients without pathological upgrading/upstaging. These results call into question the use of this endpoint to counsel patients about the merits and risks of AS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kovac E, Vertosick EA, Sjoberg DD, et al. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer. BJU Int. 2018. PMID: 29802773. doi:10.1111/bju.14418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。